Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: Systematic review and meta-analysis of randomized controlled trials

Stroke

Volumn 43, Issue 4, 2012, Pages 1058-1066

  Geeganage, Chamila M ^a   Diener, Hans Christoph ^b   Algra, Ale ^c   Chen, Christopher ^d   Topol, Eric J ^e   Dengler, Reinhard ^f   Markus, Hugh S ^g   Bath, Matthew W ^a   Bath, Philip M W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

acute ischemic stroke; antiplatelet therapy; cardiovascular prevention; transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE;

ARTICLE; BLEEDING; BRAIN ISCHEMIA; COMPARATIVE STUDY; HEART MUSCLE ISCHEMIA; HUMAN; INTERMETHOD COMPARISON; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RISK REDUCTION; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BRAIN ISCHEMIA; DATABASES, FACTUAL; DIPYRIDAMOLE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STROKE; SURVIVAL RATE; TICLOPIDINE;

EID: 84862800180     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.637686     Document Type: Article

References (42)

1. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284: 2901-2906
2. Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP. The high risk of stroke immediately after transient ischemic attack: A population-based study. Neurology. 2004;62:2015-2020 (Pubitemid 38738214)
3. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ. 2004;328:326
4. Lovett JK, Dennis MS, Sandercock PA, Bamford J, Warlow CP, Rothwell PM. Very early risk of stroke after a first transient ischemic attack. Stroke. 2003;34:e138-e140
5. Johnston SC, Leira EC, Hansen MD, Adams HP Jr. Early recovery after cerebral ischemia risk of subsequent neurological deterioration. Ann Neurol. 2003;54:439-444 (Pubitemid 37176537)
6. Johnston SC, Easton JD. Are patients with acutely recovered cerebral ischemia more unstable? Stroke. 2003;34:2446-2450 (Pubitemid 37221960)
7. Hill MD, Barber PA, Demchuk AM, Sevick RJ, Newcommon NJ, Green T, et al. Building a 'Brain attack' Team to administer thrombolytic therapy for acute ischemic stroke. CMAJ. 2000;162:1589-1593 (Pubitemid 30412383)
8. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020 (Pubitemid 32336306)
9. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008; 39:1647-1652
10. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:630S-669S (Pubitemid 351892974)
11. The European Stroke Association (ESO) Executive Committee and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457-507
12. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13 (Pubitemid 26402780)
13. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665-1673
14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339
15. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-1251
16. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649
17. International Stroke Trial Collaborative Group. The international Stroke Trial (IST); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet. 1997; 349:1569-1581
18. Kennedy J, Hill MD, Ryckborst K, Elliaziw M, Demchuk AM, Buchan AM, for FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): A randomised controlled pilot trial. Lancet Neurol. 2007;6:961-969 (Pubitemid 47562312)
19. Dengler R, Diener HC, Schwartz A, Grond M, Schumacher H, Machnig T, et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): A randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9:159-166
20. Bath PM, Cotton D, Martin RH, Palesch Y, Yusuf S, Sacco R, et al. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke. 2010;41:732-738
21. Bhatt DL, Fox KAA, Werner Hacke CB, Berger PB, Black HR, Boden WE, et al; for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717
22. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al; for MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, doubleblind, placebo-controlled trial. Lancet. 2004;364:331-337
23. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86
24. Leonardi-Bee J, Bath PM, Bousser MG, Davalos A, Diener H-C, Guiraud-Chaumeil B, Sivenius J, Yatsu F, Dewey ME, Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: A meta-analysis of individual patient data from randomized controlled trials. Stroke. 2005;36:162-168 (Pubitemid 40054197)
25. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: A meta-analysis. Stroke. 2008;39:1358-1363 (Pubitemid 351440719)
26. Sandercock PA, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2008;3: CD000029
27. Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2004; 4:CD000187
28. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev. 2007;3:CD001820
29. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;4: CD001925
30. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev. 2005;3:CD004296
31. Keller TT, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2007;3:CD005158
32. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. London: Wiley Interscience; 2008
33. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634 (Pubitemid 27387172)
34. Egger M, Smith G, Altman D. Systematic Reviews in Health Care; Meta-Analysis in Context. London: BMJ Publishing Group; 2001
35. Bloch MJ, Basile JN. Largest meta-analysis to date suggests that patients at risk for cardiovascular disease events derive benefit from antihypertensive therapy regardless of baseline blood pressure and to reduce vascular events, lowering blood pressure is more important than choice of antihypertensive drug class. J Clin Hypertens (Greenwich). 2009;11:743-745
36. King A, Markus HS. Doppler embolic signals in cerebrovascular disease and prediction of stroke risk: A systematic review and meta-analysis. Stroke. 2009;40:3711-3717
37. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation. 2005;111:2233-2240 (Pubitemid 40632440)
38. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9:489-497
39. King A, Bath PM, Markus HS. Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: A randomized trial. Stroke. 2011;42:650-655
40. Matias-Guiu J, Davalos A, Pico M, Monasterio J, Vilaseca J, Codina A. Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Acta Neurol Scand. 1987;76:413-421 (Pubitemid 18016519)
41. Kaye J, Capildeo R. A Trial to Evaluate the Relative Roles of Dipyridamole and Aspirin in the Prevention of Deep Vein Thrombosis in Stroke Patients. Bracknell: Boehringer-Ingelheim; 1989
42. Chairangsarit P, Sithinamsuwan P, Niyasom S, Udommongkol C, Nidhinandana S, Suwantamee J. Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: A preliminary study. J Med Assoc Thai. 2005;88:S148-S154.